| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754440 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 5 Pages |
Abstract
Over the past several years there has been considerable progress in the number and breadth of therapeutic options for patients with chronic lymphocytic leukemia. In particular, cumulative experience with stem cell transplant and immunotherapy has made these modalities more available to a broader range of patients. Advances in genetic engineering and ex vivo expansion techniques have sculpted cellular therapy products to optimize the combination of specificity and toxicity. This brief review discusses recent cutting-edge experience with chimeric antigen receptor T cells as well as developing cellular therapy products at the authors' institution.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Nina Shah, Katy Rezvani, Chitra Hosing, Partow Kebriaei, William Wierda, Laurence Cooper, Elizabeth Shpall,